Alzheimer's disease is one form of dementia affecting a significant proportion of the population. The etiology of this prevalent disease is currently unknown. It is postulated that AD can be treated by using stem cell-based therapies by replacing the lost neurons in the atrophic regions of the brain. For these novel therapies to be successful several sources of stem cells have been proposed, such as pluripotent stem cells as well as multipotent stem cells. Proof of concept in animal studies have shown that stem cells can grafted into the affected regions or delivered intravenously into affected parts of the brain. These experiments had improved cognition and memory performance in rodents. The promising results seen in animal models have increased interest in conducting clinical trials using the same technique. In the last 5 years, several treatments have reached phase II clinical trials.
Introduction
The prevalence of dementia is a major concern for the public health agencies all over the world. Current estimates state over 50 million people suffer from dementia globally and is expected to increase due to ageing of the population [1] . One form of dementia is due to Alzheimer's disease (AD), which is one of the leading causes of death in the United States [2] . The disease is characterized by significant atrophy in the subcortex and cerebral cortex. In the early stages of the disease patients display mild cognitive impairment, such as having problems with their short-term memory, semantic memory etc. As the disease progresses patients have shrinking vocabulary, problems communicating and the loss of long-term memory. In the advanced stages the patients become bedridden and unable to take care of themselves (Table 1) [3] . AD is classified as early onset or late onset, the latter constitutes of most of the AD cases. A significant proportion of early onset AD is familial and is manifested due to mutations in three genes: amyloid-β precursor protein (AβPP), presenilin-1 (PS-1) and presenilin-2 (PS-2) [4] . Gene knockout studies have shown that APP is involved in synapse formation [5] . Moreover AβPP is a precursor molecule that is further cleaved by secretases (such as alpha-secretase, beta secretase and gamma secretase). When AβPP is cleaved by β-secretase and γ-secretase amyloid beta (Aβ) is formed [6] . Currently the pathology of the disease is heavily debated. One of the premises of the disease is called the amyloid hypothesis, with the latest iteration being referred as the ion channel hypothesis. The notion of the hypothesis is that non-fibrillar and soluble Aβ oligomer is the most neurotoxic by forming membrane ion channels in the neurons. This allow unregulated calcium influx, leading to neuronal death [7] , [8] and colleague's research conducted at Harvard. By using a molecule that binds to Aβ called Florbetapir they showed that PET scans of one third of AD patients recruited in the study did not show signs of Aβ in their PET scans [9] . Moreover pharmacological targets identified by adhering to the amyloid hypothesis lead to failed clinical outcomes in clinical trials. In one phase I clinical trial of an experimental vaccine (AN1792) for clearing up amyloid plaques failed to slow down the progression of AD [10] . Recent phase III clinical trials have followed the same trend. Verubecestat, which inhibits Aβ production by acting as an inhibitor for β-secretase, has failed in a phase III clinical trial [11] , [12] . Similarly, a biologic was promising in animal models of AD but a phase III drug trial was terminated early due to lack of evidence [13] . Because of failure of drug development for treating AD there has been a renewed interest in stem cell-based therapies. In this review we will discuss the different sources of stem cells that can be used, proof of concept experiments using animal models and finally explore clinical trials being conducted on stem cell-based treatments for AD. [26] , [27] . NSCs in the SVZ give rise to inhibitory GABAergic and dopaminergic interneurons of the olfactory bulb whilst NSCs in DG give rise to excitatory glutamatergic granule neurons. Moreover NSCs can be readily expanded and differentiated into different neurons in vitro types making it a potential good source of stem cell transplantation for AD. Kim et al has shown that NSCs can be readily differentiated into neurons in the presence of interferon-γ and Li and colleagues have proposed that flavonoid Baicalin induces NSCs into neurons [28] , [29] . Similarly mesenchymal stem cells are (MSCs) are a type of multipotent stem cells. Whether mesenchymal stem cells (aka mesenchymal stromal cells) are true stem cells are out scope of this review. MSCs can be harvested from several sources: adipose tissues, placenta, umbilical cord blood, bone marrow, muscles etc [30] - [33] . MSCs from the adipose tissue is preferred instead of bone marrow because the procedure is less invasive [34] . MSCs can be advantageous instead of using NSCs because of their ability to differentiate into multiple lineages including neurons. A paper published in 2000 shows that that MSCs can differentiate into neural lineages, expressing nestin, in the presence of β-mercaptoethanol [35] .
Approaches for Treating AD with Stem Cells
The theoretical approaches for treating AD with stem cells can be classified into endogenous repair and exogenous repair ( (Table 4) . At this stage the safety and tolerability of the treatment are being measured on recruited patients diagnosed with the disease. One phase I clinical trial in 2011 conducted at Samsung Medical Center, South Korea evaluated the safety of using NEUROSTEM®-AD, which consists of human umbilical cord blood derived mesenchymal stem cells (Trial identifier: NCT01297218). In this trial 9 AD diagnosed patients were recruited and subjected to administration of NEUROSTEM®-AD into the hippocampus by stereotactic injection. 3 of these patients received low dose of NEUROSTEM®-AD whilst the remaining 6 patients received high dose of NEUROSTEM®-AD. The patients were followed for 2 years and showed good tolerability without severe adverse side-effects [41] . . This study will evaluate the efficacy of the treatment and is expected to end in the last quarter of 2019.
Perspective
AD is one common form of dementia, affecting over 50 million people worldwide and placing a huge burden on society [1] . This neurodegenerative disease is well characterized by extreme atrophy in hippocampus and cerebral cortex due to neuronal death. At the moment the exact triggers that instigate the neuronal loss is controversial. There have been several hypotheses postulated; with the common ones being amyloid and tau hypotheses. There have been several novel treatments proposed agreeing with this hypothesis. Unfortunately the clinical trials showed no significant benefit or were terminated early because of ethical concerns with administering treatment to thousands of patients that are unlikely to work [11] . The failure of the clinical trials raises the following questions: is it time to completely abandon this hypothesis or shall we try to intervene at the earlier stages of the disease? If we want to intervene at the early stages of the disease, at the pre-symptomatic stage, we need to develop good biomarkers for the early phase of this disease. Because of the failure of the clinical trials following the amyloid hypothesis has encouraged researchers to posit new ideas. One approach would be to promote neurogenesis by activating NSCs niches in SVG and DG of the brain. However neurogenesis drastically decreases with age and the rate of loss of neurons in AD is significantly more dramatic [36] . Also the upregulation of NSCs in SVG do not generate all neuronal subtypes and thus cannot repopulate pyramidal neurons of CA1, which is one of the neuronal subtypes affected in AD [42] . Therefore the rate of neurogenesis is unlikely to keep up with the rate of neuronal loss. Moreover in the later phases of AD the NSCs are not expected to survive therefore attempting to activate NSCs will not lead to any clinical benefit. Another approach to treat AD would be exogenous repair, such as cell replacement therapy derived from stem cells. One source of stem cells are ESCs but the spontaneous propensity of ESCs to form teratocarcinomas and their ability to generate an immune response into the host necessitates caution for clinical use [43] . The issues of ESCs host rejection can be rectified by using an autologous therapeutic approach. In this method somatic cells are taken from the patient, reprogrammed into stem like state in vitro and then transplanted back into the patient. Furthermore iPSCs are less tumorigenic than ESCs because the mutations acquired during reprogramming are mostly benign [44] . However the AD risk genes that initially aggravates AD is likely to be present in the iPSCs derived cells and thus not actually curing the disease. Before any of these novel treatments can be attempted on humans' researchers need to test them on animal models. Proof of concepts of these ideas have elicited encouraging results using ESCs as well as MSCs. Studies mentioned in this review have shown that stem cell treatments can improve learning and memory in rodents. However animal models used in these experiments obeyed amyloid hypothesis and therefore in my opinion do not fully recapitulate AD that is observed in humans. In the last 10 year there have been several clinical trials registered for treating AD using stem cellbased therapy. [38] [39] [40] [41] [42] [43] [44] [45] [46] 2020 routinely used in the clinic because none have reached stage III and IV yet and can still fail.
Conclusion
Alzheimer's disease (AD) places a huge burden on the health agencies all of over the world. At the moment there is no cure for AD but it is theorized that cell replacement therapy is one potential mechanism of treating this disease. This review has explored several preclinical studies that showed that stem cell-based therapies improve cognition and memory in AD models. The impressive results from preclinical studies have paved the way for clinical trials. It is hoped that the information gained from these clinical trials will accelerate availability of stem cell-based therapies for all hospital patients suffering from AD.
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